Loading...
The standard initial treatment for metastatic urothelial cancer has long been platinum-based chemotherapy, but only a small subset of patients achieve durable long-term disease control. While the EV-302 trial demonstrating clear superiority of enfortumab vedotin plus pembrolizumab over chemotherapy will likely change up-front management, second- and later-line therapy options will remain a critical unmet need.
Mutations in the gene encoding fibroblast growth factor receptor (FGFR) are observed in approximately 20% of advanced or metastatic urothelial cancers. Erdafitinib is a selective pan-FGFR tyrosine kinase inhibitor that is FDA approved for advanced urothelial cancer. In this pharmaceutical-sponsored, multinational, randomized phase 3 tr…